Catatan sumber primer
PenentuHasil topline
Ultragenyx: Analisis akhir Fase 3 Orbit/Cosmic untuk UX143 diperkirakan akhir 2025
Dokumen tersebut menyatakan bahwa studi Phase 3 Orbit dan Cosmic setrusumab (UX143) pada osteogenesis imperfecta sedang berjalan menuju analisis akhir setelah pasien menjalani terapi minimal 18 bulan. Data dari studi ini diharapkan sekitar akhir 2025.
Fakta utama
- Diajukan
- 4 Nov 2025, 21.12
- Peristiwa
- Hasil topline
- Arah
- Netral
- Perusahaan
RAREUltragenyx- Aset
- setrusumab
- Sumber
- SEC 8-K
- Keyakinan
- Bersumber
Kutipan sumber
EX-99.1 2 rare-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Contacts Ultragenyx Pharmaceutical Inc. Investors Joshua Higa ir@ultragenyx.com Ultragenyx Reports Third Quarter 2025 Financial Results and Corporate Update Third quarter total revenue of $160 million, Crysvita® revenue of $112 million and Dojolvi® revenue of $24 million Reaffirm 2025 Revenue Guidance: Total revenue between $640 million to $670 million, Crysvita revenue of $460 million to $480 million, and Dojolvi revenue of $90 million to $100 million Bolstered balance sheet with $400 million proceeds from sale of portion of Crysvita royalty interest NOVATO, Calif. – November 04, 2025 – Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies